Clinical trial
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410
Study timeline
Study start (actual)2023-10-18Date precision: day
Registry last updated2026-06-08
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumors With HRAS Alterationsunresolved
Non Small Cell Lung Cancer (NSCLC)unresolved
Colorectal Cancer (CRC)unresolved
Pancreatic Ductal Adenocarcinoma (PDAC)unresolved
Clear Cell Renal Cell Carcinoma (ccRCC)unresolved
Renal Cell Carcinoma (Kidney Cancer)unresolved
Interventions
DarlifarnibDRUG
CabozantinibDRUG · verified · RxNorm: cabozantinib
AdagrasibDRUG · verified · RxNorm: adagrasib
Sponsors & collaborators
Kura Oncology, Inc.lead sponsor
Mirati Therapeutics Inc.collaborator
Mapped research locations
Los AngelesCalifornia, United States3BarcelonaSpain2ParisFrance2HoustonTexas, United States1BostonMassachusetts, United States1DallasTexas, United States1St LouisMissouri, United States1NashvilleTennessee, United States1MadridSpain1PittsburghPennsylvania, United States1ColumbusOhio, United States1BerlinGermany1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06026410 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.